BioMarker Strategies earns SBIR grant
This article was originally published in The Gray Sheet
Firm is awarded a $254,000 Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop its SnapPath live-tumor-cell testing system, designed to help oncologists determine the most effective course of drug treatment for their patients. The contract allows an additional $2 million in SBIR funding once the phase one work is complete, the company notes in an Oct. 7 press release
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.